SMMT - Summit Therapeutics Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.00
DETAILS
HIGH:
$23.00
LOW:
$16.00
MEDIAN:
$18.00
CONSENSUS:
$19.00
UPSIDE:
14.32%
About Summit Therapeutics Inc. (https://www.summittxinc.com)
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Mahkam Zanganeh | Co-CEO, President & Director | 1970 | $1,025,895 GBP |
| Manmeet Singh Soni | Chief Operating Officer, Chief Financial Officer & Director | 1978 | $1,025,895 GBP |
| Robert W. Duggan | Co-CEO & Executive Chairman | 1945 | $172,376 GBP |
| Allen S. Yang | Head of R&D Strategy | 1968 | – |
| Bhaskar Anand | Chief Accounting Officer | 1977 | – |
| Dave Gancarz | Chief Business & Strategy Officer | – | – |
| Kay Elizabeth Davies | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 1951 | – |
| Laura Q. Chow | Senior Vice President of Clinical Development | – | – |
| Nathan LiaBraaten | Senior Director of Investor Relations | – | – |
| Robert LaCaze | Chief Commercial Officer | – | – |
| Urte Gayko | Chief Regulatory, Quality & Pharmacovigilance Officer | 1971 | – |
| Wang Clow Fong | Chief Biometrics Officer | 1958 | – |